earn preview select biotech
earn approach compani expect pre-report next week
provid thought select larg mid-cap biotech compani within coverag
earn guidanc well updat model select small-cap compani
preview/upd expect
glpg pti apto overal believ solid
limit risk major miss could derail recent sector momentum expect focu
potenti ep call strategi smid-cap regulatory/launch
progress drug price elect expect sector overal
found detail outlook expect discuss
brian abraham cover glpg pti
gregori renza cover apto
outperform pt base rx/sale data sever sourc believ
uptak cf cocktail trikafta exceed high expect come multipl
consensu estimate even rel conserv captur rate vs con
though appar cost rapid expect cannib particularli symdeko
vs kalydeco vs overal believ still enabl
cf sale beat despit fluid dynam manag express plan wait
late-januari earn provid next update/guid given prior histori still see
possibl pre-report and/or provid guidanc sooner especi given certainti around ex-
 reimburs trend adopt pattern model cf sale
would like leav room upsid provid guidanc estimate still
meet/exce expect reaffirm enthusiasm rapid growth potenti rais pt
valuat becom optimist believ robust trikafta launch scarciti valu
low-risk high-qual growth biotech grow enthusiasm around pipelin could drive
sector perform pt expect in-lin revenu modest beat
across ms/sma franchisesboost expect inventori buildoffset potenti downtick
royalti net minor ep beat estimate vs con
tecfidera pre-holiday uptick price increas would help minim y-o-i ms declin given tysabri
track lighter like due ocrevu inroad steadili erod ifn sma competit
expect royalti decreas find driver growth could challeng expect
guidanc revenu look similar last year our/con ep
vast major focu remain upcom tecfidera ipr decis aducanumab
regulatori updat remain cautiou
top pick pt shape in-lin quarter particular
strengthsuggest rx data epclusa estimate vs con biktrarvi vs
dramat uptick descovi use follow prep approvalthough softer legaci
product trend genvoya vs truvada vs like due cannib
effect like make tough overal bottom-lin beat estimate vs con estim
guid flattish product sale given
continu page
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
earn preview select biotech
continu page
contd potenti hcv/cp franchis product declin off-set prep/yescarta
growth reason maintain margin estimate guid
sg filgotinib launch provid reassur consensu non-gaap ep estim
alreadi reflect realist dynam estimate vs con ambisom durabl
sg spend potenti lever updat strateg initi potenti januari key
street seek proactiv capit alloc new managementt team enabl
growth visibl continu see minim downsid risk like setup valu play
limit competit price patent risk futur cash flow favor dividend yield
upsid pipelin bd success
outperform pt rx trend ingrezza continu look strong quarter
view coupl price increas enabl solid beat
buy-sid expect estimate vs sell-sid con compani like pre-
report next weekeven allow offset uptick discountinga
continu increas penetr work expand address td market base
favor trend posit kol feedback stabl share vs competitor austedo
remain ahead consensu ingrezza vs street remain somewhat
cautiou orilissa royalti vs con vs con
though recent share upsid reduc valuat disconnect believ
appreci could also come pipelin potenti launch opicapon
expect under-the-radar program like program potenti gain
increas attent investor look continu diversif around ingrezza
outperform pt expect exondi revenu in-lin
slightli consensu estimate vs con remain line
exondi revenu estimate believ vyondi launch could materi beat
expect estimate well con given like pent-up demand
histor dmd launch curv still would expect like bracket consensu
beatabl guidanc product sale call though vyondi launch
dynam casi regulatori plan interest believ investor attent
throughout primarili gene therapi manufactur progress confirmatori trial
initi high-dos limb girdl data given recent
regulatori progress clariti vyondi approv extern valid roch
around platform manufactur efficaci safeti believ srpt multi- gene
therapi pipelin increasingli derisk up-front cash on-going opex contribut
roch free addit capit potenti pursu gene therapi bolt-
on acceler develop exist earlier-stag gene therapi pipelin includ
six limb girdl therapi well even upsid recent low still see
potenti signific addit share appreci investor mani believ
sidelin await clariti path forward manufactur begin
recogn opportun rais pt increment model
outperform pt cover renza strong im sale growth trend
continu reflect increas market traction anticip nuplazid revenu
remain line expect rbc/con keep sale within
compani guidanc estimate believ solid print could
valid overal market opportun pdp well support sound basi
nuplazid expand opportun dementia-rel psychosi see come
view full harmoni data ctad decemb though updat regulatori
interact year remain key overal estim pdp drp indic could
earn preview select biotech
gener grow exceed annual late
upsid indic schizophrenia mdd area
focu parallel compani continu right stride establish infrastructur
serv broader patient marketbuild key personnel awar function
underli posit asset compani viewin order captur robust
revenu opportun avail new indic extens reiter outperform
rate pt
sector perform pt expect jakafi commerci perform continu
tend season strong sale slightli beat consensu estimate vs
con driven part price increas though ex-u jakavi royalti estimate
slightli street solid commerci momentum track
toward compani out-year goal expect
pictur question around long-term driver growth sustain remain key
come year though includ outlook gvhd program follow itacitinib recent
failur detail result success studi pend data
expect mid-year strategi secur jakafi life-cycl extens success
compani might abl pivot dermatolog key topic rux ph iii atop derm
expect mid-year whether target oncolog launch pemigatinib extend
beyond nich opportunityal balanc well compani maintain opex
disciplin estimate non-gaap d/sg y-o-i remain neutral share compani
continu work toward diversif around jakafi
outperform pt expect larg in-lin quarter oca pbc
vs con potenti guidanc pbc franchis believ
could provid call estim vs con could help reinforc
compani base valuat potenti launch oca nash draw nearer
especi given increas confid potenti indication-bas price come
icpt investor day decemb expect slightli linear oca launch curv vs
prior expect stem target commerci toward advanc
fibrosi patient plenti room nash sale beat estimate vs con
growth opportun reflect valuat acknowledg
question remain surround nash launch label price biopsi requir
physician recept continu see potenti share appreci
answer overhang subsequ lift begin adcomm tent set
outperform pt expect revenu come lower end
con est vari sourc compani like pre-report next week estim
vs con driven primarili soft emflaza estimate vs con
though could see potenti translarna beat estimate vs con
full-year expect translarna higher end con estimate vs
con import emflaza overcom reimburs headwind
competit gener prednison even face grow literatur support
emflaza long-term benefit meet consensu estim estimate vs
con even recent price increas continu expans patient
popul expect provid opex guidanc rang
unsurpris though believ street may fulli model substanti
estimate impact expect outbound gt-aadc mileston pipelin remain
import valu driver expect investor focu continu shift
market dmd product matur expand pipelin new revenu
contribut roche-partn risdiplam royalti mileston sale
earn preview select biotech
first gene therapi gt-aadc lead above-con estim total revenu
vs con believ detail late-stag risdiplam data
approv investor awar earlier-stag pipelin includ addit neuro
gene therapi oral splice modul platform huntington grow share
appreci tandem rais pt model updat
sector perform pt analysi rx data suggest
hcv market still shrink mayvret potenti lose share among
pt expect hepat sale come consensu partner
vs con drive miss enta royalti vs con
project trend lower hcv cash flow valu pipelin
valu adjust overal pt posit dataand perceiv translatabilityfrom
on-going ph ii rsv outpati trial and/or hbv progress would import help
stock break trade rang
outperform specul risk pt follow strong initi quarter
launch expect xpovio uptak remain steadi in-lin sale vs
con increas penetr late-lin myeloma popul off-label use
combin off-set like lesser contribut inventori build-up sale
believ consensu sale achiev estimate vs con albeit
contribut slightli higher myeloma slightli lower dlbcl street
current model although stock appreci consider sinc compani
report earn vs xbi reflect favor commerci dynam
play least earli increas expect boston still believ posit
ph iii data expect first month like would drive meaning addit
upsid model break sale earlier later line see potenti
boston-elig popul begin drive materi sale soon
potenti increas off-label use formal label updat data posit
glpg sector perform pt updat filgtoinib estim reflect
timelin on-going pivot adopt pattern market rheum/inflamm drug
overlap indic introduc probability-adjust royalti revenu oa
candid use updat dcf-base valuat methodolog better reflect
compani substanti balanc sheet rais pt nonetheless even
out-year filgotinib sale across indic weight po account
competit dynam arguabl increas likelihood ra approv given recent
addit evid fda permiss anim tox issu see itci caplyta
compani robust platform remain difficult us get glpg ev follow
recent appreci clinic regulatori commerci hiccup filgotinib
high-risk pipelin toledo could lead meaning share downsid
pti outperform specul risk pt key data pti cf
combo ph ii studi recent report updat model though continu expect
maintain lion share cf market assum focu pti europ market
entri uptak popul assum could
noncompliant/nonrespond see out-year annual sale potenti combin
increas po given strong ph ii data perhap underappreci
potenti well combin development cftr modul believ
nearli reflect pti current valuat even slight tweak pt
model updat
earn preview select biotech
sector perform specul risk pt updat model compani
prepar review potenti launch berotralstat previous
expect potenti approv late assum standard review timelin
adopt dynamicsand agent oral conveni albeit lesser activ would fit
prophylaxi paradigmnot like known expect investor
focu come year shift toward factor inhibitor ph poc data pnh
though ascrib signific valu program point given earli
stage increasingli crowd competit landscap expect manag provid
opex guidanc come week earn call estim
continu view reward/risk balanc overal though could see pnh data
anticip help stock bounc potenti dip
outperform specul risk pt cover renza adjust
model follow apr continu run benefit exposur
decemb see note updat readout
ph ii trial continu uncov potenti frontlin therapi md aml given low
bar standard care well high unmet patient need catalyz
see net posit continu reason rank favorit name
enrol pivot trial md remain track bring us closer target
readout ultim determin fate asset encourag
posit efficaci trend ph ii trial kol continu offer consist
favor view result increas po md
po aml addit recent initi venetoclax combo trial
aml also explor potenti expand clinic util serv
anoth posit sign around compani abil tactic execut develop
object rais pt reiter outperform specul risk
apto outperform specul risk pt cover renza refresh
model go new year follow encourag updat novel oral
inhibitor year-end apto remain favorit
pick given uniqu under-the-radar target oncolog pipelin potenti
garner increas attent clinic data develop ph trial lead asset
cll aml rais po conserv level
though data initi dose cohort remain encourag kol feedback build
clinic profil continu attest program high potenti addit wider valid
space mark mrk acquisit arql enabl greater exposur
continu believ versatil profil posit well meaning clinic
differenti combo trial commenc first half also lend addit
momentum scope util complex treatment landscap hematolog
continu advanc aml potenti b-cell cancer trial second incarn
provid addit high reward option rais pt maintain
outperform specul risk pt cover renza make sever
tweak model includ slight downward adjust po lead asset
cin base recent trial disclosur fine-tun
program time add see increment risk overal program execut
merit reflect forecast recent announc delay full reveal pivot
packag due longer anticip reveal trial enrol push
compani previous state potenti bla file month though releas
also encouragingli firm expect estim efficaci top-line reveal
earn preview select biotech
recent updat timelin direct line
peg realist runway file commerci compani recent
disclosur verifi extend time frame key data prompt us introduc even
broader cushion compani execut trial leverag new exist site
patient enrol accumul pivot data result push potenti launch
model time frame adher develop
wait meaning updat ino program includ ain/vin rrp
drive addit upsid lower pt maintain
outperform specul risk rate
stat sell day vs fx eur/usd bp q-o-q unfavor usd
strength biggest potenti beat includ vrtx trikafta con though
acknowledg reliabl con estim trikafta unclear gild epclusa
con nbix ingrezza con biib avonex con ptct
translarna con notabl potenti miss includ gild harvoni
con genvoya con vrtx symdeko enta mavyret royalti
con ptct emflaza con
new prior estim shown incom statement follow page
earn preview select biotech
valuat risk rate price target
valuat price target deriv dcf analysi base busi
discount rate termin growth rate price target support
risk rate price target risk includ lower-than-expect commerci uptak
tez/iva price pressur cf competit emerg safeti issu tripl combo
valuat price target deriv dcf use discount rate
support sector perform rate
risk rate price target risk rate price target includ competit
gener price pressur ms competit sma
valuat price target deriv via dcf analysi discount rate
termin growth rate post-taf gener price target support top
risk rate price target risk includ gener hiv entrant competit hcv
price pressur commerci scientif complex cellular car-t therapi
efficaci safeti risk pipelin product filgotinib
valuat price target blend dcf use discount rate termin
growth rate sale multipl adjust ep discount analys
multipl discount rate align valuat assumpt biotech
compani similar commerci stage size price target support outperform
risk rate price target risk includ slower-than-expect growth trajectori
ingrezza emerg real-world safeti signal chang physician
prefer ingrezza competitor austedo emerg new
competitor td landscap price pressur driven macro landscap slower-
than-expect orilissa growth inabl garner regulatori approv pipelin asset
due lack efficaci safeti signal concern disrupt nbix
valuat price target blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys price target support outperform rate
risk rate price target risk includ slower-than-anticip growth
commerci setback exondi failur gain eu approv exondi failur
success develop gain regulatori approv follow-on exon-skip drug
includ golodirsen casimersen clinic setback gene therapi program poor
perform confirmatori studi lead market remov increas patient
termin growth rate follow nuplazid patent expiri ep multipl
adjust ep discount analys valuat assumpt
earn preview select biotech
compar commerci biotech compani develop therapeut
neuropsychiatr indic price target support outperform rate
risk rate price target risk includ failur gain approv show meaning
efficaci addit indic drp mdd schizophrenia flatten growth due
lower-than-expect uptak worsen reimburs emerg safeti signal
hamper uptak result remov market lack value-cr busi
develop dilut financ greater-than anticip capit requir
valuat price target base dcf discount inci futur cash flow
annual termin growth rate begin jakafi patent expiri
probability-weight potenti favor strateg altern price target
support sector perform rate
risk rate price target downsid risk includ greater-than-expect slow
jakafi use myelofibrosi polycythemia vera inabl obtain regulatori approv
pemigatinib itacitinib topic ruxolitinib failur extend jakafi life cycl new
competit entrant price pressur jakafi olumi emerg safeti
concern market product limit efficaci signal within earlier-stag
pipelin upsid risk includ better expect uptak jakafi olumi
approv higher-dos olumi develop strategi meaning
extend jakafi life cycl potenti execut transform busi develop
valuat price target blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys price target support outperform rate
risk rate price target risk includ failur gain approv nash psc
new drug-rel safeti signal emerg unexpect increas frequenc death
liver injuri signal potenti drug-rel toxic challeng control
therapeut window trial real-world set pruritu unmanag cholesterol
increas stagnant growth pbc due label chang conservat among physician
uncertainti epidemiolog restrict reimburs competit
agent
valuat price target blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys price target support outperform rate
risk rate price target risk includ slower-than-expect ex-u launch
translarna dmd slower-than-anticip growth emflaza sale regulatori
pushback gt-aadc neg trial result sma early-stag
valuat price target blend dcf use discount rate
termin growth rate probability-adjust multipl adjust ep
discount analys valuat support sector perform rate
risk rate price target risk includ competit hcv nash/pbc
price pressur hcv potenti emerg safeti signal poor efficaci
futur clinic studi high-risk develop path rsv
earn preview select biotech
valuat price target blend dcf use discount rate termin
growth rate probability-adjust price-to-earnings multipl adjust discount
analys valuat support outperform specul risk rate
assign specul risk qualifi given unpredict futur revenu expens
non-revenu gener statu stock price volatil could result substanti
upside/downsid swing anticip valuat
risk rate price target risk includ emerg safeti signal selinexor
failur show consist efficaci signal storm sadal boston selinexor
studi toler issu limit ultim market uptak
valuat price target deriv dcf analysi base busi
discount rate termin growth rate valuat support sector
risk rate price target risk includ emerg safeti issu high regulatori
bar ra drug like filgotinib limit interpret early-stag data
valuat price target deriv blend dcf use discount
rate termin growth rate probability-adjust multipl
adjust ep discount analys price target support outperform
rate given limit later-stag clinic data date increas develop
risk believ specul risk qualifi appropri
risk rate price target pti treatment test small number
cystic fibrosi patient promis early-stag data may fail replic larger
studi singl cftr-modul compon develop adjunct therapi
alreadi approv cf treatment depend vrtx-own therapi may limit
price power lack efficaci safeti signal singl compon proprietari
triple-combo could lead clinic failur and/or delay even success develop
proprietari combin vrtx entrench cf commun physician
may difficult overcom
valuat price target blend dcf use discount rate termin
growth rate probability-adjust multipl adjust ep discount
analys price target support sector perform specul risk rate
assign specul risk qualifi given unpredict futur revenu expens
non-revenu gener statu stock price volatil could result substanti
upside/downsid swing anticip valuat
risk rate price target risk includ safeti signal emerg berotralstat
failur berotralstat demonstr clear efficaci later-stag studi poor
market penetr due competit dynam
valuat price target base blend dcf use discount
rate termin growth rate probability-adjust multipl
adjust ep discount analys valuat support outperform
specul risk rate given current market product
emerg clinic data date increas develop risk believ
specul risk qualifi appropri
earn preview select biotech
risk rate price target risk includ clinic program execut regulatori
uncertainti oncolog failur demonstr sustain efficaci trial potenti
emerg safeti signal ip risk competit hematolog cancer long-term
price pressur oncolog space
valuat price target consid blend dcf use discount rate
termin growth rate probability-adjust multipl adjust
ep discount analys valuat support outperform rate given
apto current market product limit clinic data
date increas develop risk believ specul risk qualifi
risk rate price target risk includ clinic program execut regulatori
uncertainti failur demonstr efficaci potenti emerg safeti signal
emerg competit long-term price pressur oncolog space
valuat price target deriv blend dcf cash gener
product sale use discount rate termin growth rate
probability-adjust multipl adjust ep discount analys
price target support outperform rate assign specul risk qualifi
given unpredict futur revenu expens non-revenu gener
statu stock price volatil could result substanti upside/downsid swing
anticip valuat
risk rate price target risk price target rate includ failur
phase program regulatori clinic delay safeti signal aris
ino syncon cellectra technolog failur gain approv
lower-than-anticip commerci opportun
price rate revis
earn preview select biotech
earn preview select biotech
increas near-term long-term trikafta estim base favor uptak trend suggest rx data
increas long-term orkambi estim lower out-year kalydeco symdeko estim base mix
shift cannib trend suggest rx data
earn preview select biotech
thousand except per share symdeko- probability-weight product revenu total revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
capit market estim compani report consensu
estim mm except per share item estimatesconsensu estim mm except per share item total earn preview select biotech
adjust near-term long-term ms product sale estim base latest rx data
reduc near-term long-term tysabri estim increment
revamp sma revenu build fulli integr competit dynam
remov psp sale estim model given recent data updat
adjust fx increas termin growth rate reflect pipelin depth explicitli model
biogen inc million except per share rest rest rest rest zinbryta row rest aducanumab probabl weight probabl weight opicinumab probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand gilead
earn preview select biotech
estim mm except per share item estimatesconsensu taf estim mm except per share item total hcv product earn preview select biotech
estim base rx
epclusa descovi
estim decreas
slightli base trial
timelin latest sale
dynam exist
weight damag
royalti car-t
est nash
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand neurocrin
earn preview select biotech
earn preview select biotech
increas number pt ingrezza td beyond base latest strong rx data
incorpor price increas off-set slightli tweak gross-to-net
incom statement thousand except td- hc- total revenu gener oper incom expens incom expens tax provision- comprehens incom net incom per share outstand share outstand dilut sarepta
earn preview select biotech
estim mm except per share item estimatesconsensu estimatesactualnotesexondi estim mm except per share item exondi earn preview select biotech
increas out-year opex given number pipelin program
adjust cog slightli alreadi adjust royalti increas po share count chang come
recent announc roch deal
sarepta inc thousand except per share golodirsen eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu royalties- limb girdl gene therapy- eu- research contract good gener in-licens litig licens oper incom sale intang incom chang warrant incom comprehens incom incom incom acadia
outperform pt cover renza
earn preview select biotech
earn preview select biotech
tweak out-year revenu estim slightli reflect updat sequenti penetr thereaft
incorpor price increas nuplazid effect essenti line previou price
incom statement thousand except pdp total- revenues- revenu gener oper incom expens incom expens net- net comprehens incom tax net incom per share outstand share outstand dilut
earn preview select biotech
recent adjust model reflect reduc estim po itacitinib come neg
previous adjust jakafi price increas
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust contract product cost incom net pre-tax benefit incom incom per share outstand share outstand intercept
earn preview select biotech
estim mm except per share item estimatesconsensu estim mm except per share earn preview select biotech
adjust pbc discount reflect increas confid maintain price
adjust nash run rate lower estim slightli linear ramp base revamp revenu
incom statement thousand except pbc ocaliva pbc ocaliva psc nash nash ocaliva nash licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand
earn preview select biotech
earn preview select biotech
incorpor recent emflaza price increas off-set potenti greater discount
revamp sma revenu build fulli integr competit dynam better reflect potenti launch
timet increment increas near- long-term risdiplam royalti estim
increas price estim moder penetr risdiplam
increas launch price estim lower out-year price increas gt-aadc base compani commentari
modestli increas tegsedi estim base refin market assumpt
updat share count base latest compani file
inc thousand except per share sales- royalties- net net sales- grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom enanta
earn preview select biotech
estim mm except per share item estimatesconsensu estimatesactualnotestot hcv eu mavyret/maviret estim mm except per share item hcv fy hcv earn preview select biotech
lower near- long-term hcv estim base latest rx data
revamp nash revenu build reflect latest dynam target popul
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut appendix
earn preview select biotech
earn preview select biotech
thousand except per share symdeko- probability-weight product revenu total revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
thousand except per share symdeko- probability-weight product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest aducanumab probabl weight probabl weight opicinumab probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest aducanumab probabl weight probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand sourc compani report capit market estim
earn preview select biotech
incom statement thousand except td- hc- total revenu gener oper incom expens incom expens tax provision- comprehens incom net incom per share outstand share outstand dilut
earn preview select biotech
incom statement thousand except td- hc- revenu gener oper incom expens incom expens tax provision- comprehens incom net incom per share outstand share outstand dilut
earn preview select biotech
sarepta inc thousand except per share golodirsen eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu royalties- limb girdl gene therapy- eu- research contract good gener in-licens litig licens oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
sarepta inc thousand except per share golodirsen eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu royalties- limb girdl gene therapy- eu- research contract good gener in-licens exondi litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
incom statement thousand except pdp total- revenues- revenu gener oper incom expens incom expens net- net comprehens incom tax net incom per share outstand share outstand dilut
earn preview select biotech
incom statement thousand except pdp total- revenues- revenu gener oper incom expens incom expens net- net comprehens incom tax net incom per share outstand share outstand dilut
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust contract product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust contract product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc nash nash ocaliva nash licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc ocaliva licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand
earn preview select biotech
inc thousand except per share sales- royalties- net net sales- grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom
earn preview select biotech
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut
earn preview select biotech
karyopharm thousand except share xpovio sales- mm tumors- xpovio royalties- mm probability-weight mm probability-weight tumors- grant revenu good sold includ royalti hcr gener oper incom pre-tax tax net incom per share outstand share outstand dilut
earn preview select biotech
karyopharm thousand except share xpovio sales- xpovio royalties- grant revenu good sold includ royalti hcr gener oper incom pre-tax tax net incom per share outstand share outstand dilut glpg
earn preview select biotech
galapago glpg thousand except per share royalties/profit split sales/royalties- sales/royalties- revenu sales- oper adjust short-term financi financi pre-tax result per share outstand share outstand dilut glpg
earn preview select biotech
galapago glpg thousand except per share royalties/profit split royalties- revenu sales- oper adjust short-term financi financi pre-tax result per share outstand share outstand dilut pti
earn preview select biotech
pti incom statement thousand except tripl combo ex-u total revenu good research gener total oper loss interest income- interest incom expens incom loss incom tax provision- net incom incom loss due modif prefer net incom attribut common outstand share outstand pti
earn preview select biotech
pti incom statement thousand except cf total revenu good research gener total oper loss interest income- interest incom expens incom loss incom tax provision- net incom incom loss due modif prefer net incom attribut common outstand share outstand
earn preview select biotech
incom statement thousand except sales- ex-u royalties- rapivab/rapiacta royalti collabor total revenu cost gener oper income/loss interest interest loss foreign currenc net pre-tax incom tax provision- net incom earn per share outstand share outstand
earn preview select biotech
incom statement thousand except sales- ex-u royalties- rapivab/rapiacta royalti collabor total revenu cost gener oper income/loss interest interest loss foreign currenc net pre-tax incom tax provision- net incom earn per share outstand share outstand
earn preview select biotech
incom statement thousand except revenu revenu product revenues- research develop revenue- total revenues- cost sales- research gener total oper incom loss interest interest expense- incom incom loss incom provis incom taxes- net incom foreign currenc translation- total comprehens incom earn loss per outstand basic share outstand dilut
earn preview select biotech
incom statement thousand except revenu revenu product revenues- research develop revenue- total revenues- cost sales- research gener total oper incom loss interest interest expense- incom incom loss incom provis incom taxes- net incom foreign currenc translation- total comprehens incom earn loss per outstand basic share outstand dilut apto
earn preview select biotech
apto incom statement thousand except product revenues- revenue- total revenues- cost sales- research gener total oper incom loss financ financ net financ net loss comprehens comprehens incom net pre-tax comprehens incom incom tax expense- total comprehens incom earn loss per outstand share outstand apto
earn preview select biotech
apto incom statement thousand except product revenues- revenue- total revenues- cost sales- research gener total oper incom loss financ financ net financ net loss comprehens comprehens incom net pre-tax comprehens incom incom tax expense- total comprehens incom earn loss per outstand share outstand
earn preview select biotech
incom statement thousand except sale total sale revenue- royalti milestones- collabor arrang grant total cost sales- research gener sale assets- total oper incom loss interest incom chang fair valu common stock warrant loss invest affili net pre-tax incom tax provision- net incom loss attribut non-control net incom earn loss per outstand share outstand
earn preview select biotech
incom statement thousand except sale total sale revenue- royalti milestones- collabor arrang grant total cost sales- research gener sale assets- total oper incom loss interest incom chang fair valu common stock warrant loss invest affili net pre-tax incom tax provision- net incom loss attribut non-control net incom earn loss per outstand share outstand earn preview select biotech
